Table 3.
Vaccine development for schistosomiasis.
| Agent | Description | Stage | Reference |
|---|---|---|---|
| SmCB + Montanide ISA 720 VG | Reduce parasites 63% | Schistosomula | Tallima et al26 |
| SmCB + CpG | Reduce parasites 53% | Schistosomula | Tallima et al26 |
| SmCB1 | Reduce worms burden 70% | Schistosomula | Tallima et al26 |
| SjAChE | Reduce female worms 30%–44% | Eggs and adults | You et al28 |
| Reduce fecal eggs 61%–68% | |||
| Reduce liver eggs 44%–56% | |||
| Reduce intestinal eggs 46%–48% | |||
| Reduce mature intestinal eggs 56%–63% | |||
| rSjLD1 | Reduce male worms 33% | Adults | You et al29 |
| Reduce liver granuloma density 41% | |||
| Reduce mature intestinal eggs 73% |
CpG = cytosine-guanine in the linear sequence (CpG or CG oligodeoxynucleotides); rSjLD1 = Schistosoma japonicum insulin receptor 1; SjAChE = Schistosoma japonicum acetylcholinesterace; SmCB + Montonide 720 VG = Schistosoma mansoni chaptesin B + Montanide ISA 720 VG (SEPPIC Inc., Fairfield, NJ, USA); SmCB1 = Schistosoma mansoni chaptesin B1; VG = vegetable-grade.